ARHGAPs, or Rho GTPase activating proteins, are a family of proteins that regulate Rho GTPases, which are critical for cell signaling. Rho GTPases are molecular switches that control various cellular processes, including cytoskeletal dynamics, cell migration, and proliferation. They cycle between an active GTP-bound state and an inactive GDP-bound state. ARHGAP proteins facilitate the transition of Rho GTPases from their active to inactive form by increasing their intrinsic GTPase activity. This regulation is crucial for maintaining cellular homeostasis and responding to extracellular signals. Dysregulation of Rho GTPase signaling can lead to various diseases, including cancer, underscoring the importance of ARHGAPs in cell biology.
Targeting ARHGAPs for disruption or inhibition has emerged as a potential strategy in diseases where Rho GTPase signaling is aberrant. Inhibiting specific ARHGAPs can modulate the activity of Rho GTPases, thereby altering cellular behaviors that contribute to disease progression. For example, in cancer, targeting ARHGAPs could disrupt tumor cell migration and invasion. However, this approach requires careful consideration of the specific ARHGAP and tissue context, as Rho GTPases play diverse roles in different cell types. Additionally, targeting ARHGAPs poses challenges in achieving specificity and avoiding unintended effects on normal cellular functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fasudil, Monohydrochloride Salt | 105628-07-7 | sc-203418 sc-203418A sc-203418B sc-203418C sc-203418D sc-203418E sc-203418F | 10 mg 50 mg 250 mg 1 g 2 g 5 g 10 g | $18.00 $33.00 $87.00 $168.00 $253.00 $496.00 $910.00 | 5 | |
ROCK inhibitor that may stabilize ARHGAP activity through decreased pathway feedback. | ||||||
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | $104.00 $364.00 | 7 | |
Another Rho kinase inhibitor that could potentially influence ARHGAP39’s regulatory actions on Rho GTPases. | ||||||
EHT 1864 | 754240-09-0 | sc-361175 sc-361175A | 10 mg 50 mg | $213.00 $889.00 | 12 | |
Rac1 inhibitor that could reduce ARHGAP-mediated signaling by stabilizing inactive Rac1. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Inhibits Trio, a GEF, potentially modifying ARHGAP-mediated GTPase activity. | ||||||
Rhosin | 1173671-63-0 | sc-507401 | 25 mg | $555.00 | ||
Selectively inhibits RhoA binding to GEF, possibly modulating ARHGAP's regulatory effects. | ||||||
Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor Inhibitor | 509093-47-4 | sc-204013 | 5 mg | $163.00 | 2 | |
Cdc42 activity-specific inhibitor, might adjust ARHGAP's regulatory impact. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
Cdc42 inhibitor, which could affect downstream processes regulated by ARHGAP. | ||||||
PAC 1 | 315183-21-2 | sc-203174 sc-203174A | 10 mg 50 mg | $132.00 $536.00 | 1 | |
Inhibits cytohesins, potentially influencing ARHGAP activity indirectly. | ||||||
RKI-1447 | 1342278-01-6 | sc-472590 | 1 mg | $330.00 | ||
Inhibits the interaction between JMY and RhoA, thus indirectly influencing ARHGAP's activity within the Rho GTPase pathway. | ||||||